Frankfurt - Delayed Quote EUR

Towa Pharmaceutical Co., Ltd. (6QC.F)

Compare
15.50
-0.40
(-2.52%)
At close: 8:33:52 AM GMT+2
Loading Chart for 6QC.F
  • Previous Close 15.90
  • Open 15.50
  • Bid 15.30 x --
  • Ask 16.40 x --
  • Day's Range 15.50 - 15.50
  • 52 Week Range 15.50 - 20.60
  • Volume 50
  • Avg. Volume 0
  • Market Cap (intraday) 780.592M
  • Beta (5Y Monthly) -0.23
  • PE Ratio (TTM) 6.40
  • EPS (TTM) 2.42
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield 0.49 (3.11%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan.

www.towayakuhin.co.jp

4,588

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 6QC.F

View More

Performance Overview: 6QC.F

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

6QC.F
155.57%
Nikkei 225 (^N225)
12.93%

1-Year Return

6QC.F
18.77%
Nikkei 225 (^N225)
11.95%

3-Year Return

6QC.F
92.34%
Nikkei 225 (^N225)
25.55%

5-Year Return

6QC.F
6.14%
Nikkei 225 (^N225)
94.92%

Compare To: 6QC.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6QC.F

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    800.74M

  • Enterprise Value

    2.00B

  • Trailing P/E

    6.56

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.50

  • Price/Book (mrq)

    0.75

  • Enterprise Value/Revenue

    1.28

  • Enterprise Value/EBITDA

    10.64

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.61%

  • Return on Assets (ttm)

    3.16%

  • Return on Equity (ttm)

    12.13%

  • Revenue (ttm)

    253.35B

  • Net Income Avi to Common (ttm)

    19.28B

  • Diluted EPS (ttm)

    2.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.25B

  • Total Debt/Equity (mrq)

    132.22%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 6QC.F

View More

Company Insights: 6QC.F

Research Reports: 6QC.F

View More